|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2008中西方BNP专家共识显示文摘1.前言
2008年6月,来自中国、美国、欧洲的急诊科、心血管科、实验室及内科临床专家相聚在中国上海。 | Alan Maise Christian Mueller W. Frank Peacock Gerasimos Filippatos Hu Dayi 胡大一(主译) 刘梅颜(主译) 吴寸草(翻译) 王博雅(翻译) 黄睿(翻译) | 2009 | 中国医药导刊2009，11，10： | 76 |
| 2 | Hyponatremia in patients with heart failure显示文摘The present review analyses the mechanisms relating heart failure and hyponatremia,describes the association of hyponatremia with the progress of disease and morbidity/mortality in heart failure patients and presents treatment options focusing on the role of arginine vasopressin(AVP)-receptor antagonists.Hyponatremia is the most common electrolyte disorder in the clinical setting and in hospitalized patients.Patients with hyponatremia may have neurologic symptoms since low sodium concentration produces brain edema,but the rapid correction of hyponatremia is also associated with major neurologic complications.Patients with heart failure often develop hyponatremia owing to the activation of many neurohormonal systems leading to decrease of sodium levels.A large number of clinical studies have associated hyponatremia with increased morbidity and mortality in patients hospitalized for heart failure or outpatients with chronic heart failure.Treatment options for hyponatremia in heart failure,such as water restriction or the use of hypertonic saline with loop diuretics,have limited efficacy.AVP-receptor antagonists increase sodium levels effectively and their use seems promising in patients with hyponatremia.However,the effects of AVP-receptor antagonists on hard outcomes in patients with heart failure and hyponatremia have not been thoroughly examined. | Theodosios D Filippatos Moses S Elisaf | 2013 | World Journal of Cardiology2013，5，9： | 13 |
| 3 | Effects of glucagon-like peptide-1 receptor agonists on renal function显示文摘Glucagon-like peptide-1(GLP-1)receptor agonists result in greater improvements in glycemic control than placebo and promote weight loss with minimal hypoglycemia in patients with type 2 diabetes mellitus.A number of case reports show an association of GLP-1receptor agonists,mainly exenatide,with the development of acute kidney injury.The present review aims to present the available data regarding the effects of GLP-1 receptor agonists on renal function,their use in subjects with chronic renal failure and their possible association with acute kidney injury.Based on the current evidence,exenatide is eliminated by renal mechanisms and should not be given in patients with severe renal impairment or end stage renal disease.Liraglutide is not eliminated by renal or hepatic mechanisms,but it should be used with caution since there are only limited data in patients with renal or hepatic impairment.There is evidence from animal studies that GLP-1 receptor agonists exert protective role in diabetic nephropathy with mechanisms that seem to be independent of their glucose-lowering effect.Additionally,there is evidence that GLP-1 receptor agonists influence water and electrolyte balance.These effects may represent new ways to improve or even prevent diabetic nephropathy. | Theodosios D Filippatos Moses S Elisaf | 2013 | World Journal of Diabetes2013，4，5： | 9 |
| 4 | Role of ezetimibe in non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging from simple steatosis to steatohepatitis,advanced fibrosis and inflammatory changes.Ezetimibe inhibits cholesterol absorption from the intestinal lumen into enterocytes.The molecular target of ezetimibe is the sterol transporter Niemann-Pick C1-like 1 protein (NPC1L1).Human NPC1L1 is abundantly expressed in the liver and may facilitate the hepatic accumulation of cholesterol.Ezetimibe ex-erts beneficial effects on several metabolic variables.Ezetimibe treatment attenuates hepatic steatosis and is beneficial in terms of NAFLD biochemical markers.The combination of ezetimibe with other interventions may also be beneficial in NAFLD patients.Our group inves-tigated the ezetimibe-orlistat combination treatment in overweight and obese patients with hypercholeste-rolemia,with beneficial effects on NAFLD biochemical markers.These results are promising for patients with NAFLD,who usually have increased cardiovascular disease risk and need a multifactorial treatment.How-ever,it should be mentioned that most results are from animal studies and,although modest elevation of liver function tests may raise the suspicion of NAFLD,none of these tests are sensitive to establish the diagnosis of NAFLD with great accuracy. | Theodosios D Filippatos Moses S Elisaf | 2011 | World Journal of Hepatology2011，3，10： | 4 |
| 5 | Thiazide-associated hyponatremia in the elderly: what the clinician needs to know显示文摘导致 Thiazide 的 hyponatremia 是在老个人的减少的钠层次的主要原因之一。这评论关于联系 thiazide 的 hyponatremia 介绍当前的证据。联系 Thiazide 的 hyponatremia 与象收到 thiazides 的大剂量的那些那样的某些风险因素主要在病人被观察,有许多 comorbidity,例如心失败,肝疾病或恶意,并且拿几药,例如 non-steroidal 反煽动性的药,选择血清素重新举起禁止者或 tricyclic 抗抑郁剂。钠集中应该为开发联系 thiazide 的 hyponatremia 与风险因素在病人被监视,临床医生们应该即时与显示减少的钠层次的神经符号在病人测量浆液钠层次。有联系 thiazide 的 hyponatremia 的病人的临床、生物化学的侧面可以是细胞外的体积弄空或不恰当的尿分泌抑制剂荷尔蒙分泌物(SIADH ) 的症候群的。可能的联系 thiazide 的 hyponatremia 的调查由于 thiazides (弄空相关的细胞外的体积或象 SIADH 一样) 包括减少的钠层次的另外的原因和 hyponatremia 的特征的鉴定的排除。治疗应该小心地被监视由于 overcorrection 避免严肃的神经复杂并发症。临床医生们应该阻止与联系利尿剂的 hyponatremia 的历史在病人规定 thiazides 并且应该为开发联系 thiazide 的 hyponatremia 与风险因素在病人比较喜欢 thiazides 的低剂量。 | George Liamis Theodosios D Filippatos Moses S Elisaf | 2016 | Journal of Geriatric Cardiology2016，13，2： | 3 |
| 6 | Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia显示文摘 | Vasilis Tsimihodimos Irene Gazi Theodosios Filippatos Michael Kostapanos Kostantinos Lagos Christina Kostara Constantinos C. Tellis Moses Elisaf Alexandros D. Tselepis | 2009 | Atherosclerosis2009，，2： | 2 |
| 7 | Combination drug treatment in patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease (NAFLD) includes simple steatosis, a benign condition, and non-alcoholic steatohepatitis, a condition that beyond TG accumulation also includes necroinflammation and fibrosis. An association between NAFLD and cardiovascular disease (CVD) has been recently suggested. NAFLD patients usually have an increased CVD risk profile. NAFLD is also associated with metabolic syndrome (MetS) and is considered as the hepatic component of MetS by some authors. Currently, the only established treatment of NAFLD is gradual weight loss. However, multifactorial treatment of NAFLD risk factors may be needed to reduce the increased CVD risk of NALFD patients. Drug combinations that include antiobesity drugs (such as orlistat and sibutramine) and target CVD risk factors may be a good approach to NAFLD patients. Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistatezetimibe and sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction and improvement of liver function tests. Small studies give promising results but double-blind, randomized trials examining the effects of such multifactorial treatment in hard CVD endpoints in NAFLD patients are missing. | Theodosios D Filippatos Moses S Elisaf | 2010 | World Journal of Hepatology2010，2，4： | 2 |
| 8 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008显示文摘 | Dickstein K Cohen-Solal A Filippatos G | | European Heart Journal0，，： | 2 |
| 9 | Depression in coronary artery disease: Novel pathophysiologicmechanisms and therapeutic implications显示文摘 | Parissis JT Fountoulaki K Filippatos G | 2007 | Int J Cardiol2007，116，2： | 1 |
| 10 | Treatment of hyperlipidaemia with fenofibrate andrelated fibrates显示文摘 | Filippatos T Milionis HJ | 2008 | Expert Opin Investig Drugs2008，17，10： | 1 |
| 11 | Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure显示文摘 | Spiros P. Kourouklis Emmanouil Vagiakis Ioannis A. Paraskevaidis Dimitrios Farmakis Konstantinos Kostikas John T. Parissis Apostolos Katsivas Dimitrios T. Kremastinos Maria Anastasiou-Nana Gerasimos Filippatos | 2012 | International Journal of Cardiology2012，，： | 1 |
| 12 | ESPEN Guidelines on P-arenteral Nutrition:on cardiology and pneumology显示文摘 | Anker SD Laviano A Filippatos G | | 0，，04： | 1 |
| 13 | Guidelines for the di- agnosis and treatment of acute and chronic heart failure显示文摘 | Dickstein K Cohen-Solal A Filippatos G | 2008 | Europe- an Heart Journal2008，29，19： | 1 |
| 14 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial显示文摘 | John R Teerlink Gad Cotter Beth A Davison G Michael Felker Gerasimos Filippatos Barry H Greenberg Piotr Ponikowski Elaine Unemori Adriaan A Voors Kirkwood F Adams Maria I Dorobantu Liliana R Grinfeld Guillaume Jondeau Alon Marmor Josep Masip Peter S Pang | 2013 | The Lancet . 2013 (9860)2013，，9860： | 1 |
| 15 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study显示文摘 | T. D. Filippatos D. N. Kiortsis E. N. Liberopoulos M. Georgoula D. P. Mikhailidis M. S. Elisaf | 2005 | Current Medical Research and Opinion?2005，，12： | 1 |
| 16 | Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure显示文摘 | Ali Ahmed Robert C. Bourge Gregg C. Fonarow Kanan Patel Charity J. Morgan Jerome L. Fleg Inmaculada B. Aban Thomas E. Love Clyde W. Yancy Prakash Deedwania Dirk J. van Veldhuisen Gerasimos S. Filippatos Stefan D. Anker Richard M. Allman | 2014 | The American Journal of Medicine2014，，1： | 1 |
| 17 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008显示文摘 | Dickstein K Cohen-Solal A Filippatos G | 2008 | Eur Heart 12008，29，3： | 1 |
| 18 | Deterrainants of plasma NT- pm-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction 显示文摘 | Letsas KP Filippatos GS Pappas LK | 2009 | Clin Res Cardiol2009，98，2： | 1 |
| 19 | Ef- fects of plant sterols and stanols beyond low density lipoprotein cholesterol lowering 显示文摘 | Derdemezis CS Filippatos TD Mikhailidis DP | 2010 | Cardiovasc Pharmacol Ther2010，，3： | 1 |
| 20 | ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008of the European Society of Cardiology显示文摘 | Dickstein K Cohen-SolaI A Filippatos G et a1 | 2008 | Eur J Heart Fail2008，10，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员